Find Information About:

Drugs & Supplements

Get information and reviews on prescription drugs, over-the-counter medications, vitamins, and supplements. Search by name or medical condition.

Pill Identifier
WebMD

Pill Identifier

Having trouble identifying your pills?

Enter the shape, color, or imprint of your prescription or OTC drug. Our pill identification tool will display pictures that you can compare to your pill.

Get Started
My Medicine
WebMD

My Medicine

Save your medicine, check interactions, sign up for FDA alerts, create family profiles and more.

Get Started

WebMD Health Experts and Community

Talk to health experts and other people like you in WebMD's Communities. It's a safe forum where you can create or participate in support groups and discussions about health topics that interest you.

  • Second Opinion
    WebMD

    Second Opinion

    Read expert perspectives on popular health topics.

  • Community
    WebMD

    Community

    Connect with people like you, and get expert guidance on living a healthy life.

Got a health question? Get answers provided by leading organizations, doctors, and experts.

Get Answers

Sign up to receive WebMD's award-winning content delivered to your inbox.

Sign Up

Breast Cancer Health Center

Font Size
A
A
A

Genetics of Breast and Ovarian Cancer (PDQ®): Genetics - Health Professional Information [NCI] - Psychosocial Issues in Inherited Breast and Ovarian Cancer Syndromes

Table 15. Uptake of Risk-reducing Salpingo-oophorectomy (RRSO) and/or Gynecologic Screening AmongBRCA1andBRCA2Mutation Carriers

Study Citation Study Population Uptake of RRSO Uptake of Gynecologic Screening Length of Follow-up Comments
CA-125 = cancer antigen 125; RRM = risk-reducing mastectomy; TVUS = transvaginal ultrasound.
a Self-report as data source.
b Medical records as data source.
c Data source not specified.
United States
Scheuer et al. (2002)[225] Carriers (n = 179)a Carriers 50.3% CA-125 Mean, 24.8 mo; range, 1.6-66.0 mo Women undergoing RRSO were older and more likely to have a personal history of breast cancer.
- Carriers 67.6%
TVUS
- Carriers 72.9%
Beattie et al. (2009)[217] Carriers (n = 240)b Carriers 51% Not applicable Mean, 3.7 y Women opting for RRSO <60 y had a prior diagnosis of breast cancer and also underwent RRM.
Median time to RRSO: 123 days from receiving results.
O'Neill et al. (2010)[218] Carriers (n = 146)a Carriers 32% Not applicable 12 mo
Schwartz et al. (2012)[219] Carriers (n = 100)a Carriers 65% CA-125 Mean, 5.3 y Predictors of RRSO were being ≥40 y and having received a diagnosis of breast cancer more than 10 y ago.
Noncarriers (n = 52)a Noncarriers 1.9% - Carriers 56%
- Noncarriers 12%
- Uninformative 33%
Uninformative (n = 203)a Uninformative 13.3% TVUS
- Carriers 42%
- Noncarriers 20%
- Uninformative 26%
Garcia et al. (2013)[220] Carriers (n = 305)b Carriers 74% Excluding women post-RRSO: 41 mo; range, 26-66 mo Ovarian surveillance decreased significantly from years 1-5 of follow-up; CA-125: 47% to 2%; TVUS: 45% to 2.3%
CA-125
- Carriers 47%
TVUS
- Carriers 45%
Mannis et al. (2013)[226] Carriers (n = 201)a Carriers 69.6% CA-125 Median, 3.7 y Predictors of RRSO and screening included being aBRCAmutation carrier, age 40-49 y, having a higher income, ≥2 children, a personal history of breast cancer, and a first-degree relative with ovarian cancer.
- 26.3%
TVUS
- 26.3%
Noncarriers (n = 103)a Noncarriers 2.0% Not reported
Uninformative (n = 773)a; 59/773 with a variant of uncertain significance Uninformative 12.3% CA-125
- 10.4%
TVUS
- 6.5%
Singh et al. (2013)[221] Carriers (n = 136)b Carriers 52% Not applicable Range, 1-11 y Predictors of RRSO were first- or second-degree relative with breast cancer, a mother lost to pelvic cancer, having had ≥1 childbirths, age ≥50 y, and having undergone testing after 2005.
International
Phillips et al. (2006)[222] Carriers (n = 70)a Carriers 29% CA-125 3 y
- Carriers 0%
TVUS
- Carriers 67%
Friebel et al. (2007)[227] Carriers (N = 537)c Carriers 55% Not applicable Minimum 6 mo; median 36 mo RRSO greatest in parous women >40 y.
Madalinska et al. (2007)[228] Carriers (n = 160)a, b Carriers 74% Carriers 26% 12 mo Women who underwent RRSO had lower education levels, viewed ovarian cancer as incurable, and believed strongly in the benefits of RRSO.
Specific method(s) of gynecological screening not reported.
Metcalfe et al. (2008)[223] Carriers (N = 2,677)a Carriers 57% Not applicable 3.9 y; range, 1.5-10.3 y Large differences in uptake of risk management options by country.
Julian-Reynier et al. (2011)[224] Carriers (n = 101)a Carriers 42.6% TVUS 5 y RRSO uptake increased with age. Having undergone RRSO did not alter breast cancer risk perception. Noncarriers often continued screening.
Noncarriers (n = 145)a Noncarriers 2% - Noncarriers 43.2%
Rhiem et al. (2011)[229] Carriers (N = 306)b Carriers 57% Not evaluated Mean, 47.8 mo post-oophorectomy Median age at time of RRSO = 47 y. One occult fallopian tube cancer was detected at the time of RRSO. One peritoneal carcinoma was diagnosed 26 mo post-RRSO.
Sidon et al. (2012)[230] Carriers (N = 700)a; 386/700 with personal history of breast cancer BRCA1carriers: Not evaluated Affected with breast cancer Uptake of RRSO was lower in women >60 y (22% uptake at 5 y). None of the women >70 y had a RRSO performed.
- 54.5%
BRCA2 carriers: -BRCA1: Mean, 2.29; range, 0.1-11.45 y
- 45.5%
All carriers with no personal history of breast cancer -BRCA2: Mean, 1.77; range, 0.1-11.1 y
Not affected with breast cancer
- 54.2%
All carriers with personal history of breast cancer -BRCA1: Mean, 1.63; range, 0.1-11.28 y
- 43.2% -BRCA2:Mean, 1.75; range, 0.1-8.98 y
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46
Next Article:

Today on WebMD

Breast Cancer Overview
From self-exams and biopsies to reconstruction, we’ve got you covered.
Dealing with breast cancer
Get answers to your questions.
 
woman having mammogram
Experts don’t agree on all fronts, but you can be your own advocate.
woman undergoing breast cancer test
Many women worry. But the truth? Most abnormalities aren’t breast cancer.
 
Breast Cancer Treatments Improving
VIDEO
Resolved To Quit Smoking
SLIDESHOW
 
Woman getting mammogram
Article
Screening Tests for Women
SLIDESHOW
 
ovarian cancer overview slideshow
SLIDESHOW
serious woman
Article
 
what is your cancer risk
HEALTH CHECK
10 Ways to Revitalize Slideshow
SLIDESHOW